Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178391310> ?p ?o ?g. }
- W3178391310 endingPage "983" @default.
- W3178391310 startingPage "983" @default.
- W3178391310 abstract "Abstract MCL1 is a member of the anti-apoptotic BCL2 family of proteins and plays a critical role in maintaining cellular homeostasis and promoting cell survival. It is frequently amplified in cancer and increased expression of MCL1 is associated with a higher grade and poor prognosis in multiple tumor types. Importantly, MCL1 has been implicated in mediating resistance to chemotherapy as well as targeted therapies, including the BCL2 inhibitor, venetoclax. Here, we describe the in vitro and in vivo activity of PRT1419, a potent and selective inhibitor of human MCL1, that can induce tumor cell death by apoptosis. PRT1419 inhibits the binding of MCL1 to its physiological ligand, BIM, with low nanomolar potency. PRT1419 also demonstrated >200-fold selectivity against other BCL2 family members, including BCL2 and BCL-XL. In vitro, PRT1419 treatment resulted in robust activation of apoptotic markers such as cleaved caspase-3 in a concentration-dependent manner in several cancer cell lines. Consistent with its pro-apoptotic effects, PRT1419 treatment led to robust inhibition of cell proliferation in a concentration-dependent manner in a panel of cancer cell lines. Cell lines representing hematologic cancers as well as a subset of breast and non-small cell lung cancer lines were sensitive to PRT1419, and this response was associated with a significantly higher MCL1/BCL-XL mRNA ratio. Also, PRT1419 treatment resulted in potent, concentration-dependent cytotoxic activity ex vivo in patient-derived xenograft (PDX) models of various subtypes of human sarcoma, breast and esophageal cancer. PRT1419 demonstrated good oral bioavailability and favorable pharmacokinetic properties in vivo. In subcutaneous cell-line derived xenograft (CDX) models of multiple myeloma, acute myeloid leukemia (AML) and diffuse large B-cell lymphoma, oral administration of PRT1419 demonstrated potent anti-tumor activity with complete tumor regressions observed at tolerable doses. This response correlated with a dose-dependent induction of cleaved caspase-3 and cleaved-PARP in tumor tissue. Significant in vivo activity, including complete responses, was also observed in PDX models of lymphoma. In preclinical models of solid tumors, PRT1419 demonstrated significant tumor growth inhibition in a PDX model of human soft tissue sarcoma and a CDX model of breast cancer. PRT1419 was also tested in combination with other approved targeted therapies in vitro and in vivo. In AML, combining PRT1419 with a BCL2 inhibitor revealed a synergistic interaction in cell lines, ex vivo PDX models as well as a CDX model in vivo. Further, PRT1419 demonstrated synergistic activity with tyrosine kinase inhibitors to inhibit the proliferation of breast, melanoma, and non-small cell lung cancer cell lines. PRT1419 is currently under evaluation in a Phase I clinical trial in patients with relapsed/refractory hematologic malignancies (NCT04543305). Citation Format: Neha Bhagwat, Alexander Grego, William Gowen-MacDonald, Min Wang, Miles Cowart, Xiaowei Wu, Jincong Zhuo, Andrew Combs, Bruce Ruggeri, Peggy Scherle, Kris Vaddi. Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 983." @default.
- W3178391310 created "2021-07-19" @default.
- W3178391310 creator A5015102287 @default.
- W3178391310 creator A5018193992 @default.
- W3178391310 creator A5022438790 @default.
- W3178391310 creator A5034085965 @default.
- W3178391310 creator A5036665836 @default.
- W3178391310 creator A5046355139 @default.
- W3178391310 creator A5060435781 @default.
- W3178391310 creator A5066102937 @default.
- W3178391310 creator A5069730078 @default.
- W3178391310 creator A5083674171 @default.
- W3178391310 creator A5082918002 @default.
- W3178391310 date "2021-07-01" @default.
- W3178391310 modified "2023-09-25" @default.
- W3178391310 title "Abstract 983: Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1" @default.
- W3178391310 doi "https://doi.org/10.1158/1538-7445.am2021-983" @default.
- W3178391310 hasPublicationYear "2021" @default.
- W3178391310 type Work @default.
- W3178391310 sameAs 3178391310 @default.
- W3178391310 citedByCount "10" @default.
- W3178391310 countsByYear W31783913102021 @default.
- W3178391310 countsByYear W31783913102022 @default.
- W3178391310 countsByYear W31783913102023 @default.
- W3178391310 crossrefType "journal-article" @default.
- W3178391310 hasAuthorship W3178391310A5015102287 @default.
- W3178391310 hasAuthorship W3178391310A5018193992 @default.
- W3178391310 hasAuthorship W3178391310A5022438790 @default.
- W3178391310 hasAuthorship W3178391310A5034085965 @default.
- W3178391310 hasAuthorship W3178391310A5036665836 @default.
- W3178391310 hasAuthorship W3178391310A5046355139 @default.
- W3178391310 hasAuthorship W3178391310A5060435781 @default.
- W3178391310 hasAuthorship W3178391310A5066102937 @default.
- W3178391310 hasAuthorship W3178391310A5069730078 @default.
- W3178391310 hasAuthorship W3178391310A5082918002 @default.
- W3178391310 hasAuthorship W3178391310A5083674171 @default.
- W3178391310 hasConcept C104317684 @default.
- W3178391310 hasConcept C121608353 @default.
- W3178391310 hasConcept C126322002 @default.
- W3178391310 hasConcept C127561419 @default.
- W3178391310 hasConcept C150903083 @default.
- W3178391310 hasConcept C185592680 @default.
- W3178391310 hasConcept C190283241 @default.
- W3178391310 hasConcept C207001950 @default.
- W3178391310 hasConcept C26291073 @default.
- W3178391310 hasConcept C2777938653 @default.
- W3178391310 hasConcept C2778461978 @default.
- W3178391310 hasConcept C2779176958 @default.
- W3178391310 hasConcept C2779675984 @default.
- W3178391310 hasConcept C31573885 @default.
- W3178391310 hasConcept C502942594 @default.
- W3178391310 hasConcept C54355233 @default.
- W3178391310 hasConcept C55493867 @default.
- W3178391310 hasConcept C71924100 @default.
- W3178391310 hasConcept C81885089 @default.
- W3178391310 hasConcept C86803240 @default.
- W3178391310 hasConcept C96232424 @default.
- W3178391310 hasConcept C98274493 @default.
- W3178391310 hasConceptScore W3178391310C104317684 @default.
- W3178391310 hasConceptScore W3178391310C121608353 @default.
- W3178391310 hasConceptScore W3178391310C126322002 @default.
- W3178391310 hasConceptScore W3178391310C127561419 @default.
- W3178391310 hasConceptScore W3178391310C150903083 @default.
- W3178391310 hasConceptScore W3178391310C185592680 @default.
- W3178391310 hasConceptScore W3178391310C190283241 @default.
- W3178391310 hasConceptScore W3178391310C207001950 @default.
- W3178391310 hasConceptScore W3178391310C26291073 @default.
- W3178391310 hasConceptScore W3178391310C2777938653 @default.
- W3178391310 hasConceptScore W3178391310C2778461978 @default.
- W3178391310 hasConceptScore W3178391310C2779176958 @default.
- W3178391310 hasConceptScore W3178391310C2779675984 @default.
- W3178391310 hasConceptScore W3178391310C31573885 @default.
- W3178391310 hasConceptScore W3178391310C502942594 @default.
- W3178391310 hasConceptScore W3178391310C54355233 @default.
- W3178391310 hasConceptScore W3178391310C55493867 @default.
- W3178391310 hasConceptScore W3178391310C71924100 @default.
- W3178391310 hasConceptScore W3178391310C81885089 @default.
- W3178391310 hasConceptScore W3178391310C86803240 @default.
- W3178391310 hasConceptScore W3178391310C96232424 @default.
- W3178391310 hasConceptScore W3178391310C98274493 @default.
- W3178391310 hasIssue "13_Supplement" @default.
- W3178391310 hasLocation W31783913101 @default.
- W3178391310 hasOpenAccess W3178391310 @default.
- W3178391310 hasPrimaryLocation W31783913101 @default.
- W3178391310 hasRelatedWork W2004172311 @default.
- W3178391310 hasRelatedWork W2011115045 @default.
- W3178391310 hasRelatedWork W2013765863 @default.
- W3178391310 hasRelatedWork W2073863642 @default.
- W3178391310 hasRelatedWork W2084547689 @default.
- W3178391310 hasRelatedWork W2463515876 @default.
- W3178391310 hasRelatedWork W2475187007 @default.
- W3178391310 hasRelatedWork W2913223560 @default.
- W3178391310 hasRelatedWork W4206614737 @default.
- W3178391310 hasRelatedWork W4235616939 @default.
- W3178391310 hasVolume "81" @default.
- W3178391310 isParatext "false" @default.
- W3178391310 isRetracted "false" @default.
- W3178391310 magId "3178391310" @default.